People On The Move

Specialty Pharma

 

 

Yutaka Niihara, M.D., MPH, has been reapppointed CEO of Emmaus Life Sciences Inc. Dr. Niihara is co-founder and chairman of the company. Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases.

Paul Korner, M.D., M.B.A., has been made executive VP and chief medical of Ardelyx Inc. Dr. Korner was president, Ferring International Pharmascience Center U.S. Inc. (FIPCUS) and senior VP, U.S. Development, for Ferring Pharmaceuticals. Ardelyx is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative, minimally systemic, small molecule therapeutics that work exclusively in the gastrointestinal tract to treat gastrointestinal and cardio-renal diseases.

Andres A. Gutierrez, M.D., Ph.D., is now chief medical officer of Sellas Life Sciences Group. Before joining Sellas, Dr. Gutierrez served as medical director, ECTR Immuno-oncology at Bristol-Myers Squibb Co. Sellas is focused on innovative products to treat cancers and central nervous system (CNS) diseases.

Scott Garrett, M.B.A., is now VP of commercial planning at Huya Bioscience International. Garrett has more than 20 years of commercial experience in both drugs and devices for oncology and cardiovascular disease with companies such as Celladon, Mallinckrodt, Gilead, Johnson & Johnson, Boston Scientific, and Nycomed Amersham. Huya is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China.

Richard Mohs, Ph.D., has become VP of clinical development at AgeneBio Inc. Most recently, Dr. Mohs served as Eli Lilly’s VP for Neuroscience Early Clinical Development and Distinguished Research Fellow within Lilly Research Laboratories. AgeneBio is a development-stage CNS biopharmaceutical company developing innovative therapeutics aimed at preserving and restoring brain function for unserved patients afflicted with neurological and psychiatric diseases.

Indranil Nandi, Ph.D., has been made VP, Research & Development, at Vertice Pharma. Dr. Nandi served as VP, Generic Research & Development for Impax Laboratories. Vertice Pharma develops, manufactures, markets, and distributes high-quality and affordable pharmaceutical products through its operating companies.

Biopharma/Biotherapeutics

Robert Shepard, M.D., F.A.C.P., has become chief medical officer, and Panna L. Dutta, Ph.D., is appointed VP of drug development and manufacturing at PDS Biotechnology. Most recently, Dr. Shepard served as the global lead for several ongoing cancer trials at AstraZeneca, including prostate and breast cancer trials. Dr. Dutta joined PDS from The Medicines Company, where he led the successful approval and launch of Kengreal, an injectable platelet inhibitor.

Sanuj Ravindran, M.D., is appointed chief business officer of aTyr Pharma Inc. Dr. Ravindran’s most recent role was senior VP and global head, corporate development, at The Medicines Company.

Service Companies

GalbraithWight has made several appointments. Eithne McShane has become global business development director, Europe. McShane has extensive market access experience from her previous roles with Bayer, Novartis Oncology and Therabel Europe. Steve Mazzarese is now global business development director, Launch Excellence. Mazzarese held previous roles with Wolters Kluwer, Cegedigm, and IMS. Ilsu Labat-Camy was appointed senior consultant and account manager, Europe. Labat-Camy previously spent 17 years at Servier, Boehringer Ingelheim, SantaFarma, and NovoNordisk in a range of affiliate and international senior marketing, commercial and management roles. Lup Yee Yau is now senior consultant, Asia Pacific. Yau has extensive international experience from more than 20 years with Boehringer Ingelheim in European, Global, and Asia Pacific roles. Andrea Schatke is now senior consultant, Schatke was head of marketing for Astellas Austria. Julie Green and Vittoria de Ghislanzoni-Cardoli are project support managers in Milan, Italy. Mel Dearing, who has been a member of the team for four years in the United Kingdom, now takes on new responsibilities for digital and graphic execution in addition to her new project support manager role. GalbraithWight is a global market access consultancy.

Denise Tenerelli has taken on the role of senior VP of operations at Ashfield Healthcare LLC. Tenerelli was previously VP, Global Commercial Services, at Shire Pharmaceuticals. Glen E. Martin was appointed senior VP, Medical Sciences, at Ashfield Commercial and Medical Services. Before joining Ashfield, he was executive director for Celgene. Ashfield provides commercial and medical services to healthcare companies.